Offer Update

AstraZeneca PLC
06 June 2007

(NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART, IN, INTO OR
FROM AUSTRALIA, CANADA OR JAPAN OR ANY OTHER JURISDICTION WHERE TO DO SO WOULD
CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OF SUCH JURISDICTION)



      AstraZeneca Successfully Completes Tender Offer for MedImmune Shares



AstraZeneca PLC ('AstraZeneca') today announced that it successfully completed
its tender offer for all of the outstanding shares of common stock of MedImmune,
Inc. ('MedImmune').  The subsequent offering period for the offer expired at 12:
00 midnight, New York City time, on Tuesday, June 5, 2007.  AstraZeneca
Biopharmaceuticals Inc., a wholly owned subsidiary of AstraZeneca, purchased in
the initial and subsequent offering periods of the offer a total of
approximately 218,750,474 MedImmune shares (excluding shares tendered through
notices of guaranteed delivery which have not to date been received),
representing approximately 91.6% of the outstanding shares of MedImmune.


As previously announced, AstraZeneca expects to effect, without a vote or
meeting of MedImmune's stockholders, a short-form merger on or about June 18,
2007 to complete the MedImmune acquisition.  Following the merger, MedImmune
will be an indirect wholly owned subsidiary of AstraZeneca.  In the merger, each
of the remaining shares of MedImmune common stock (other than any shares in
respect of which appraisal rights are validly exercised under Delaware law and
any shares owned by MedImmune, AstraZeneca or any of their subsidiaries) will be
converted into the right to receive the same $58.00 in cash per share, without
interest, that was paid in the tender offer.  Following the merger, MedImmune's
common stock will cease to be traded on the NASDAQ Global Select Market.


                                     -Ends-

June 6th 2007


AstraZeneca
Media Enquiries:
Steve Brown / Edel McCaffrey (London)                        [phone]/5034
Staffan Ternby (Sweden)                                      (8) 553 26107
Emily Denney (Wilmington)                                    [phone]
Analyst/Investor Enquiries:
Jonathan Hunt / Mina Blair / Karl Hard  (London)             [phone]/5084/5322
Staffan Ternby (Sweden)                                      (8) 553 26107
Ed Seage / Jorgen Winroth (US)                               [phone]/[phone]
Merrill Lynch (Financial Adviser to AstraZeneca)             [phone]
Richard Girling
Deutsche Bank (Joint Corporate Broker to AstraZeneca)        [phone]
Charlie Foreman
Goldman Sachs (Joint Corporate Broker to AstraZeneca)        [phone]
Phil Raper

MedImmune

Media Enquiries:
Jamie Lacey                                                  301-398-4035
Analyst/Investor Enquiries:
Pete Vozzo                                                   301-398-4358



Not for release, publication or distribution, in whole or in part, in, into or
from Australia, Canada or Japan


                      This information is provided by RNS
            The company news service from the London Stock Exchange